Skip to main content
Clinical Trials/NCT00842023
NCT00842023
Completed
Phase 4

A Randomized Controlled Trial to Evaluate Renal Function, Inflammatory Mediators, and Neurohormonal Markers in Acutely Decompensated Heart Failure Patients Receiving Nesiritide Compared to Nitroglycerin.

Western University of Health Sciences1 site in 1 country89 target enrollmentJuly 2006

Overview

Phase
Phase 4
Intervention
Nesiritide
Conditions
Acute Decompensated Heart Failure
Sponsor
Western University of Health Sciences
Enrollment
89
Locations
1
Primary Endpoint
Renal Function by Serum Creatinine
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.

Detailed Description

No additional details provided

Registry
clinicaltrials.gov
Start Date
July 2006
End Date
February 2009
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sheryl Chow

Associate Professor

Western University of Health Sciences

Eligibility Criteria

Inclusion Criteria

  • At least 18 years of age.
  • Subject must be able to understand the potential risks and benefits associated with the study.
  • Baseline systolic blood pressure ≥ 90 mm Hg at the time of enrollment.
  • Clinical symptoms of dyspnea and laboratory admission BNP levels \> 500 pg/mL.
  • Neither pregnant or breastfeeding at the time of enrollment.
  • Authorization of patient's enrollment by patient's medical provider.

Exclusion Criteria

  • \<18 years of age
  • Denies written informed consent
  • Pregnant or lactating.
  • Baseline systolic BP \< 90 mmHg or cardiogenic shock
  • No symptoms of congestion or admission BNP \< 500 pg/mL
  • Known allergy to E.coli-derived products, or any history of anaphylactic reactions to nesiritide.
  • Receiving dialysis at the time of enrollment.
  • Serum creatinine \> 2.5 mg/dL at the time of enrollment.

Arms & Interventions

Nesiritide Infusion

Nesiritide: 2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.

Intervention: Nesiritide

Nitroglycerin Infusion

Nitroglycerin was initiated at 10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP\<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.

Intervention: Nitroglycerin

Outcomes

Primary Outcomes

Renal Function by Serum Creatinine

Time Frame: Baseline, 24 hours, 48 hours

Serum creatinine values and changes in serum creatinine

Study Sites (1)

Loading locations...

Similar Trials